CTRI/2018/10/016195已完成未知
A Prospective, Randomized, Double Blinded, Placebo-Controlled, Parallel Group, Proof of Concept Study to Assess the Effect of Nutraceutical Formulations in Apparently Healthy Adults with Mildly Impaired Respiratory Function due to Chronic Exposure to Highly Polluted Environment - NA
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subject is male or female, 18-60 years of age;
- •2. Subject should have respiratory symptoms score >=10, as assessed by Part 1 of SGRQ;
- •3. Subject has FEV1 >=70% of predicted;
- •4. Subject is currently not consuming any medication for respiratory
- •symptoms or respiratory impairment;
- •5. Subject has been residing in a highly polluted urban area (AQI >100)
- •without interruption since at least 6 months; Interruption defined as the
- •subject being away from highly polluted urban area for more than 2 weeks
- •in the last 6 months;
- •6. Subject is literate and can read/write;
- •7. Subject should be willing to maintain habitual diet and physical activity
- •patterns during the study period;
- •8. Female subjects of childbearing potential should have a negative serum
- •pregnancy test (human chorionic gonadotropin, beta subunit [β-hCG]) at
- •9. Male and female subjects of childbearing potential should be willing to
- •practice appropriate birth control during the entire duration of the study.
- •Appropriate birth control is defined in the study as any medically
- •recommended method (or combination of methods) except oral birth
- •control pills as per standard of care;
- •10. Subject has laboratory investigations within normal reference range. If
- •abnormal laboratory values, they should be deemed as not clinically
- •significant by principal investigator for hematology and biochemistry;
- •Note: If the subject is included in the study as per investigator discretion
- •based on abnormal non-clinically significant laboratory values, the details
- •of subject inclusion will be recorded in CRF;
- •11. Subject tests negative for hepatitis B surface antigen (HbsAg), antihepatitis C virus antibodies, and anti-HIV antibodies at screening;
- •12. Subject is willing to provide written informed consent;
- •13. Subject is willing, able and likely to comply with all study procedures and restrictions.
排除标准
- •1.Subject has known allergies to the herbal products or allergy to any of the components of the study product;
- •2.Subject has a history or presence of clinically important respiratory disease (including but not limited to uncontrolled asthma, chronic obstructive pulmonary disease, and restrictive lung disease) or such disease is detected at the time of screening and requires active treatment.(Note: Subjects with mild obstructive respiratory diseases requiring treatment only on â??as neededâ?? basis can be included in the study. Such subjects will have to undergo a washout period of 6-8 hours prior to spirometry evaluation at all visits, including screening visit).
- •3. Subject has current or past history of smoking;
- •4. Subject has difficulty swallowing tablets that could affect ability to consume the study product;
- •5. Subject has hemoglobin level of <11 g/dL;
- •6. Subject had an upper or lower respiratory tract infection within 2 weeks prior to screening;
- •7. Subject with history of use of medications known to affect respiratory function (e.g. bronchodilators, anti-histaminics, theophyllines, leukotriene antagonists, mast-cell stabilizers, benztropine, inhaled/systemic corticosteroids, beta-blockers, angiotensin converting enzyme inhibitors, opioids etc) or any other medications in the opinion of investigator that may interfere with study outcomes, in the past 1 month.
- •8. Subjects with a history of use of other herbal or nutritional supplements including multivitamin/multi-mineral supplements that modify pulmonary function in the past 6 months and is unwilling to refrain from their use through the duration of the trial;
- •9. Subject with history of significant renal, hepatic, cardiovascular, hematologic, metabolic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular, neurologic, endocrine dysfunction, malignancy (except basal cell carcinoma), or any other significant medical illness or disorder which, in the judgment of the investigator could interfere with the study or require treatment(s) which might interfere with study or which may pose risk to the patient;
- •10. History of drug abuse or alcohol consumption in the past 12 months.
- •Note: If the subject is a social drinker (i.e. <20 g/day in case of females and
- •<30 g/day in case of males), he/she will be included in the study.
- •11. History of participation in any other clinical study within last 60 days;
- •12. Subject is pregnant or breast-feeding at the time of screening, or planning
- •to be pregnant during the study;
- •13. Any other condition that in the investigatorâ??s judgment, might interfere
- •with study objectives.
研究者
相似试验
已完成
不适用
A study to assess effects of Nutraceutical formulations in Pre-diabetic Subjects.CTRI/2018/09/015586Amway India Enterprises Pvt Ltd56
进行中（未招募）
1 期
A Randomised, Prospective, Double Blinded, Placebo Controlled Trial to Determine the Efficacy of Continuous Infusion Ankle Block Compared to Standard Single Bolus Block in the Management of Postoperative Pain Following Foot and Ankle Surgery - Ankle Block StudyAny Orthopaedic condition which would require ankle or hind foot surgery under Mr. James Calder at North Hampshire Hospital, Basingstoke.EUCTR2005-006172-35-GBorth Hampshire Hospital NHS Trust56
已完成
不适用
A Randomised, Prospective, Double Blinded, Placebo Controlled Trial to Determine the Efficacy of Continuous Infusion Ankle Block Compared to Standard Single Bolus Block in the Management of Postoperative Pain Following Foot and Ankle SurgeryISRCTN57941461Record Provided by the NHSTCT Register - 2006 Update - Department of Health56
进行中（未招募）
1 期
Planned, randomized trial where placebo is used and the drug. No one would know which subject has the drug and which one has placebo. Trial is phase 3 study and will study how safe and effective the drug is with subjects who have Advanced or Metastatic Gastric Cancer (GC)Advanced or Metastatic Gastric CancerEUCTR2016-003984-20-PLSK BioPartners, Inc459
进行中（未招募）
1 期
Planned, randomized trial where placebo is used and the drug. No one would know which subject has the drug and which one has placebo. Trial is phase 3 study and will study how safe and effective the drug is with subjects who have Advanced or Metastatic Gastric Cancer (GC)Advanced or Metastatic Gastric CancerEUCTR2016-003984-20-DEElevar Therapeutics, Inc459